FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform - KIVIRID

FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform

Authors: Asher Mullard

Published: 2022-02-10

DOI: 10.1038/d41573-022-00031-3

Source: Full article

Abstract

No abstract found.